EUVIMEDEUVIMED entdecken
Open Access

Pan-antiviral effects of a PIKfyve inhibitor on respiratory virus infection in human nasal epithelium and mice

Jonathan Baker, Hugo Ombredane, Leah Daly, Ian Knowles, Garth Rapeport, Kazuhiro Ito iD

Antimicrobial Agents and Chemotherapy · 10.01.2024 · 68 (1)

DOI: 10.1128/aac.01050-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 10.01.2024. Verfasst von Jonathan Baker und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Heart and Lung Institute, Imperial College , London, United Kingdom. Hauptthemen laut MEDLINE: Influenza, Human, Hemorrhagic Fever, Ebola. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: SubIntro Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endocytosis, or internalization through endosomes, is a major cell entry mechanism used by respiratory viruses. Phosphoinositide 5-kinase (PIKfyve) is a critical enzyme for the synthesis of phosphatidylinositol (3, 5)biphosphate (PtdIns (3, 5)P2) and has been implicated in virus trafficking via the endocytic pathway. In fact, antiviral effects of PIKfyve inhibitors against SARS-CoV-2 and Ebola have been reported, but there is little evidence regarding other respiratory viruses. In this study, we demonstrated the antiviral effects of PIKfyve inhibitors on influenza virus and respiratory syncytial virus in vitro and in vivo . PIKfyve inhibitors Apilimod mesylate (AM) and YM201636 concentration-dependently inhibited several influenza strains in an MDCK cell-cytopathic assay. AM also reduced the viral load and cytokine release, while improving the cell integrity of human nasal air-liquid interface cultured epithelium infected with influenza PR8. In PR8-infected mice, AM (2 mg/mL), when intranasally treated, exhibited a significant reduction of viral load and inflammation and inhibited weight loss caused by influenza infection, with effects being similar to oral oseltamivir (10 mg/kg). In addition, AM demonstrated antiviral effects in RSV A2-infected human nasal epithelium in vitro and mouse in vivo , with an equivalent effect to that of ribavirin. AM also showed antiviral effects against human rhinovirus and seasonal coronavirus in vitro . Thus, PIKfyve is found to be involved in influenza and RSV infection, and PIKfyve inhibitor is a promising molecule for a pan-viral approach against respiratory viruses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza, HumanHemorrhagic Fever, EbolaHumansAnimalsMiceOseltamivirAntiviral AgentsNasal Mucosa

Stichwörter der Autor:innen

ApilimodPIKfyveair-liquid interfacecoronavirushuman rhinovirusinfluenzarespiratory syncytial virus

Substanzen

OseltamivirAntiviral Agents

Autor:innen und Institutionen

  • National Heart and Lung Institute, Imperial College , London, United Kingdom.
  • Pharmidex , London, United Kingdom.

ORCID-Profile: Kazuhiro Ito

Förderung

  • SubIntro Ltd.

Zitieren

APA

Baker, J., Ombredane, H., Daly, L., Knowles, I., Rapeport, G., & Ito, K. (2024). Pan-antiviral effects of a PIKfyve inhibitor on respiratory virus infection in human nasal epithelium and mice. Antimicrobial Agents and Chemotherapy, 68(1). https://doi.org/10.1128/aac.01050-23

Vancouver

Baker J, Ombredane H, Daly L, Knowles I, Rapeport G, Ito K. Pan-antiviral effects of a PIKfyve inhibitor on respiratory virus infection in human nasal epithelium and mice. Antimicrobial Agents and Chemotherapy. 2024;68(1). doi:10.1128/aac.01050-23

BibTeX
@article{Baker2024,
  author = {Baker, Jonathan and Ombredane, Hugo and Daly, Leah and Knowles, Ian and Rapeport, Garth and Ito, Kazuhiro},
  title = {Pan-antiviral effects of a PIKfyve inhibitor on respiratory virus infection in human nasal epithelium and mice},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  volume = {68},
  number = {1},
  doi = {10.1128/aac.01050-23}
}
Kostenlos starten →